ALNOV:EPA
Novacyt SA
0,41 €
0,00%
(0,00) 1 d.
6. nov., 17:35:21 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,41 €
Augsta
0,41 €
Zema
0,40 €
Tirgus kapitalizācija
27,19 milj.
Vid. apjoms
187,71 tūkst.
Apjoms
119,78 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,41 €
Augsta
0,41 €
Zema
0,40 €
Tirgus kapitalizācija
27,19 milj.
Vid. apjoms
187,71 tūkst.
Apjoms
119,78 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
BigGo Finance
·
pirms 1 stundas
Goldman Sachs Panic Index Breaches Extreme 9.5 Threshold; History Shows S&P 500 Averaged 4.6% Gain Over Following Three Months
CryptoRank
·
pirms 6 minūtēm
S&P 500 Earnings Beats Shrink to Just 2.7%, Weakest in Four Years Despite 84% of Companies Topping Forecasts
FXLeaders
·
pirms 20 minūtēm
Dow Futures and Nasdaq Futures Rise Despite Microsoft-Oracle News
Bloomberg
·
pirms 47 minūtēm
Asian Markets at Risk of Pressure on Nvidia Probe: Markets Wrap
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnenovacyt.com